专题:Cancer Treatment and Pharmacology

This cluster of papers focuses on the chemotherapy-induced peripheral neuropathy (CIPN) experienced by cancer patients, particularly in the context of breast cancer treatment. It covers various aspects such as the neurotoxic effects of taxanes and oxaliplatin, neuroprotective strategies, and the impact of CIPN on the quality of life of patients. Additionally, it discusses the use of microtubule-targeting agents like Eribulin Mesylate in cancer treatment.
最新文献
近5年高被引文献
Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics

article Full Text OpenAlex 1844 FWCI95.9739

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

article Full Text OpenAlex 1223 FWCI91.8897

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

article Full Text OpenAlex 523 FWCI53.8075

Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook

article Full Text OpenAlex 516 FWCI50.0017

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

article Full Text OpenAlex 494 FWCI77.6175

NCCN Guidelines® Insights: Breast Cancer, Version 4.2023

article Full Text OpenAlex 453 FWCI43.5729

The Time Toxicity of Cancer Treatment

article Full Text OpenAlex 349 FWCI48.5461

Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

article Full Text OpenAlex 317 FWCI36.8185

Pharmacological Effects of Cisplatin Combination with Natural Products in Cancer Chemotherapy

article Full Text OpenAlex 308 FWCI22.4936

Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship

review Full Text OpenAlex 307 FWCI14.6609